Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

GE HealthCare Technologies' market position, rising earnings, and improving financials make it an attractive investment opportunity. Read more on GEHC stock.

We all forget things. Names, dates, phone chargers – even why we walked into the kitchen. It’s called being human… or, let’s be honest, being over 40 in a digital world with too many tabs open in our ...

Globally, it is estimated that someone develops dementia every three seconds, and the number of people living with dementia is expected to reach 78 million by 2030.The progressive neurodegenerative ...

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...